These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18220590)

  • 1. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues.
    Aguilar-Salinas CA; Mehta R; Rojas R; Gómez-Pérez FJ; Olaiz G; Rull JA
    Curr Diabetes Rev; 2005 May; 1(2):145-58. PubMed ID: 18220590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome.
    Venkatapuram S; Shannon RP
    Am J Ther; 2006; 13(1):64-71. PubMed ID: 16428924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiometabolic risk management in type 2 diabetes and obesity.
    Taylor AM
    Curr Diab Rep; 2008 Oct; 8(5):345-52. PubMed ID: 18778582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications.
    Meerarani P; Badimon JJ; Zias E; Fuster V; Moreno PR
    Curr Mol Med; 2006 Aug; 6(5):501-14. PubMed ID: 16918371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic syndrome: diagnosis and treatment.
    Zieve FJ
    Clin Cornerstone; 2004; 6 Suppl 3():S5-13. PubMed ID: 15707265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there specific components of the insulin resistance syndrome that predict the increased atherosclerosis seen in type 2 diabetes mellitus?
    Golden SH; Chong R
    Curr Diab Rep; 2004 Feb; 4(1):26-30. PubMed ID: 14764276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.
    Krentz AJ
    Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifactorial aspects of the treatment of the type II diabetic patient.
    Colwell JA
    Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.
    Bonora E; Targher G; Formentini G; Calcaterra F; Lombardi S; Marini F; Zenari L; Saggiani F; Poli M; Perbellini S; Raffaelli A; Gemma L; Santi L; Bonadonna RC; Muggeo M
    Diabet Med; 2004 Jan; 21(1):52-8. PubMed ID: 14706054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
    Ferdinand KC
    J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS).
    Sone H; Tanaka S; Iimuro S; Oida K; Yamasaki Y; Oikawa S; Ishibashi S; Katayama S; Ito H; Ohashi Y; Akanuma Y; Yamada N
    J Atheroscler Thromb; 2009 Aug; 16(4):380-7. PubMed ID: 19672033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications.
    Eschwège E
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S19-27. PubMed ID: 14502097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Falko JM; Moser RJ; Meis SB; Caulin-Glaser T
    Curr Diabetes Rev; 2005 May; 1(2):127-35. PubMed ID: 18220588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-prandial hypertriglyceridemia in patients with type 2 diabetes mellitus with and without macrovascular disease.
    Kumar V; Madhu SV; Singh G; Gambhir JK
    J Assoc Physicians India; 2010 Oct; 58():603-7. PubMed ID: 21510110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update.
    Ganne S; Arora SK; Dotsenko O; McFarlane SI; Whaley-Connell A
    Curr Diab Rep; 2007 Jun; 7(3):208-17. PubMed ID: 17547838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabolic syndrome].
    Boursier V
    J Mal Vasc; 2006 Sep; 31(4 Pt 1):190-201. PubMed ID: 17088787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis?
    Milionis HJ; Florentin M; Giannopoulos S
    CNS Spectr; 2008 Jul; 13(7):606-13. PubMed ID: 18622365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.